From Heartburn to Hospitalization: A Case of Milk-Alkali Syndrome

Introduction: Milk-alkali syndrome (MAS) was initially associated with the "Sippy regimen", a cocktail of milk and bicarbonates for peptic ulcer disease. Although the incidence of MAS declined with the use of acid-suppressive therapy, it has resurged in recent decades due to increased use of over-the-counter calcium and alkali supplements. This paper highlights MAS as an underrecognized cause of hypercalcemia and outlines the management challenges it poses compared to other etiologies of hypercalcemia. Case Description: A 72-year-old female presented with acute confusion and nonsensical speech following a fall. Collateral history revealed a 10-day history of worsening epigastric pain and poor oral intake, which she attributed to her reflux disease. In an attempt to self-treat, she consumed approximately 25 tablets daily of calcium carbonate (tums) 500 mg. Labs revealed severe hypercalcemia (corrected calcium >19 mg/dL), metabolic alkalosis (bicarbonate 34 mmol/L), hypokalemia (2.8 mmol/L), hypomagnesemia (1.0 mg/dL), suppressed PTH (19 pg/mL), normal PTH-related peptide (<2 pmol/L) normal calcitriol (<7 pg/mL), normal creatinine (1.12 mg/dL), and a negative immunofixation. Her clinical presentation was consistent with MAS, and she was treated with intravenous fluids, calcitonin, and zoledronic acid. Her mental status improved alongside the normalization of her calcium levels and improved oral intake. However, rebound hypocalcemia became the primary barrier to discharge, necessitating intravenous calcium supplementation and delaying her transition to outpatient care. Discussion: MAS is typically linked to intake >4g/day of elemental calcium, though it can occur with <2g/day when risk factors like, chronic kidney disease, vitamin D supplements, diuretics, or renin-angiotensin system blockers are present. In this case, MAS resulted from 25 daily Tums tablets, equating to 5g of elemental calcium. Early diagnosis is crucial. Unlike malignancy-related hypercalcemia, rebound hypocalcemia is common in MAS, making bisphosphonates inappropriate. This case highlights MAS as a reversible but underrecognized cause of hypercalcemia and encephalopathy, with treatment often complicated by overcorrection and prolonged hospitalization.

Authors

Institutions

Publication Details

Journal
Journal of the American Society of Nephrology
Published
2025-10-01
DOI
https://doi.org/10.1681/asn.2025eqj8sy90
Primary Topic
Gastrointestinal disorders and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

From Heartburn to Hospitalization: A Case of Milk-Alkali Syndrome

Muhammad Riaz Khan, Krishnakumar D. Hongalgi, Swati Mehta, Sidrah Abid et al.
Journal of the American Society of Nephrology
Gastrointestinal disorders and treatments
article

From Heartburn to Hospitalization: A Case of Milk-Alkali Syndrome

Muhammad Riaz Khan, Krishnakumar D. Hongalgi, Swati Mehta, Sidrah Abid, Aman Pal
article en

Abstract

Introduction: Milk-alkali syndrome (MAS) was initially associated with the "Sippy regimen", a cocktail of milk and bicarbonates for peptic ulcer disease. Although the incidence of MAS declined with the use of acid-suppressive therapy, it has resurged in recent decades due to increased use of over-the-counter calcium and alkali supplements. This paper highlights MAS as an underrecognized cause of hypercalcemia and outlines the management challenges it poses compared to other etiologies of hypercalcemia. Case Description: A 72-year-old female presented with acute confusion and nonsensical speech following a fall. Collateral history revealed a 10-day history of worsening epigastric pain and poor oral intake, which she attributed to her reflux disease. In an attempt to self-treat, she consumed approximately 25 tablets daily of calcium carbonate (tums) 500 mg. Labs revealed severe hypercalcemia (corrected calcium >19 mg/dL), metabolic alkalosis (bicarbonate 34 mmol/L), hypokalemia (2.8 mmol/L), hypomagnesemia (1.0 mg/dL), suppressed PTH (19 pg/mL), normal PTH-related peptide (<2 pmol/L) normal calcitriol (<7 pg/mL), normal creatinine (1.12 mg/dL), and a negative immunofixation. Her clinical presentation was consistent with MAS, and she was treated with intravenous fluids, calcitonin, and zoledronic acid. Her mental status improved alongside the normalization of her calcium levels and improved oral intake. However, rebound hypocalcemia became the primary barrier to discharge, necessitating intravenous calcium supplementation and delaying her transition to outpatient care. Discussion: MAS is typically linked to intake >4g/day of elemental calcium, though it can occur with <2g/day when risk factors like, chronic kidney disease, vitamin D supplements, diuretics, or renin-angiotensin system blockers are present. In this case, MAS resulted from 25 daily Tums tablets, equating to 5g of elemental calcium. Early diagnosis is crucial. Unlike malignancy-related hypercalcemia, rebound hypocalcemia is common in MAS, making bisphosphonates inappropriate. This case highlights MAS as a reversible but underrecognized cause of hypercalcemia and encephalopathy, with treatment often complicated by overcorrection and prolonged hospitalization.

Journal of the American Society of NephrologyVol. 36(10S)
Albany Medical Center Hospital (US)
Openalex Percentile: Top 52%
Gastrointestinal disorders and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.